CompanyPPCBNasdaqCamberwell, Victoria, C3

Propanc Biopharma, Inc.

Propanc Biopharma develops pancreatic proenzyme therapies targeting cancer stem cells.

SEC EDGAR ClinicalTrials.gov propanc.com

10-KSep 25Latest SEC filing

Jul 17Latest story

July 2026

Propanc Biopharma's S-1 details 1:25 reverse split and Hexstone resale terms

Jul 17FinancingPropanc Biopharma, Inc.

Propanc Biopharma board member departs, accountant Carlo Campiciano appointed to replace her

Jul 14PeoplePropanc Biopharma, Inc.